Short answer
Lexeo Therapeutics, Inc. (LXEO) filed an 8-K current report with the SEC on June 15, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). LX2006 regulatory update for Friedreich ataxia cardiomyopathy, including pivotal-study design supporting potential accelerated approval.
Lexeo Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- LX2006 regulatory update for Friedreich ataxia cardiomyopathy, including pivotal-study design supporting potential accelerated approval
- Conference call and webcast scheduled for June 15, 2026 at 8:00 a.m. ET
- Updated corporate presentation signals refreshed investor messaging on LX2006 and broader gene-therapy pipeline
- Accelerated approval pathway remains subject to clinical results, regulatory acceptance, trial execution, and liquidity risks
Item EX-99.1 · Exhibit EX-99.1
- LX2006 pivotal SUNRISE-FA 2 protocol finalized, supporting potential accelerated-approval BLA submission in first half of 2028
- Randomized open-label design: 13 LX2006-treated participants versus 13 untreated controls
- Primary endpoint LVMI, powered for at least 15% effect, with topline efficacy analysis at 6 months
- First patient expected by end of June 2026; topline data anticipated in second half of 2027
- FDA removed cardiac frataxin co-primary endpoint and requires no additional nonclinical bridging studies
Other items in this filing:
- Item 7.01: Regulation FD Disclosure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lexeo Therapeutics, Inc. 8-K filings
Get the next LXEO 8-K as it lands
Follow LXEO for push alerts, or ask the research agent what this filing means.